Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07717073
Active, not recruiting Observational

MyocarditIRM-Génétique - Genetic Sub-study of the French Cohort of Acute Myocarditis Cases Diagnosed by MRI

NCT07717073 · tracked via the Priya Life Science France tracker
Sponsor
French Cardiology Society
Phase
Observational
Started
2025-07-15
Last updated
2026-07-21

Condition(s) studied

Acute Myocarditis

Study summary

The aim of this retrospective, non-interventional study is to assess the prevalence and describe the genetic variants found in a cohort of patients with acute myocarditis confirmed by MRI. This is a study linked to the MyocarditIRM cohort, designed to collect genetic test results obtained as part of routine clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient enrolled in MyocarditIRM * Patient who has undergone genetic testing Exclusion Criteria: * Patient who has objected to the reuse of their data

Primary outcome measure(s)

  • Prevalence and characterization of genetic variants (genes involved and ACMG classification) in patients with MRI-confirmed acute myocarditis. — From index hospitalization for acute myocarditis up to 10 years of follow-up (including SNDS linkage when available)

Trial sites (1)

FacilityCityRegionStatus
CHU de Poitiers Poitiers France

More French Cardiology Society trials in France

Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control Recruiting
Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation Recruiting
MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease Recruiting
Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery Recruiting
Microflow3D - Non-invasive Mapping of Coronary Arteries and the Cerebral Vascular Network Using 3D Ultrasound Localization Microscopy in Patients With Atherosclerosis Prior to Carotid Endarterectomy Surgery Starting soon

Other trials for the same condition

Colchicine Versus Placebo in Acute Myocarditis Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07717073 on ClinicalTrials.gov ↗ ← All trials in France